Regorafenib plus avelumab in advanced neuroendocrine tumors — and the IDO1 biomarker that predicts resistance
Why do gastric cancers resist PD-1 plus antiangiogenesis? Spatial and plasma profiling points to M2 macrophages
Can an oncolytic virus turn “cold” sarcomas hot? Intratumoral JX-594 with avelumab raised CD8 T cells but not responses
TROP2 expression and response to immune checkpoint inhibition in patients with advanced non-small cell lung cancer
Background Monoclonal antibodies targeting programmed cell death-1, or PD-1, and its ligand PD-L1 have revolutionized the treatment of patients with advanced non-small cell lung cancer. However, most patients with advanced NSCLC display primary resistance to PD1/PD-L1 blockade. Identifying targetable alterations involved in resistance represents a promising approach to improve immunotherapy efficacy. TROP2 expression is associated […]
Why intravenous oncolytic virus JX-594 lit up immune biomarkers but not tumor responses in HR+ breast cancer
Why the TLR4 agonist G100 boosted T cells but not PD-1 response in “cold” soft tissue sarcoma
Why systemic oncolytic virus JX-594 stirred an immune signal but not clinical benefit in soft tissue sarcoma
Can a simple blood test predict who responds to immunotherapy? Circulating L-arginine tracks checkpoint-inhibitor survival
How tolerogenic cDC1 dendritic cells “educate” inflammatory cDC2 by exporting the tryptophan metabolite L-kynurenine
Does acetaminophen blunt cancer immunotherapy? Plasma evidence links paracetamol to worse checkpoint-inhibitor outcomes
